| Home | E-Submission | Sitemap | Editorial Office
Korean J Hepatol > Volume 14(1); 2008 > Article
The Korean Journal of Hepatology 2008;14(1): 58-66.
doi: https://doi.org/10.3350/kjhep.2008.14.1.58
Factors affecting initial virologic response and emergence of resistant mutants after adefovir treatment in lamivudine-resistant chronic hepatitis B patients
Jin Hee Cho, M.D., Jae Youn Cheong, M.D., Joon Koo Kang, M.D., Jin Sun Park, M.D., Myoung Hee Lee, M.D., Nam Kyu Lim, M.D., Sun Pyo Hong, PhD.1, Soo-Ok Kim, PhD.1, Wang Don Yoo, PhD.1, and Sung Won Cho, M.D.
Department of Gastroenterology, Ajou University School of Medicine, Suwon, Korea, 1GeneMatrix Inc, Yongin, Korea

Adefovir dipivoxil (adefovir) effectively inhibits both wild-type and lamivudine-resistant hepatitis B virus (HBV) replication. The development of adefovir resistance is both delayed and infrequent compared with lamivudine resistance. The aim of this study was to characterize the serologic, biochemical, and virologic response to adefovir, and to explore the factors affecting initial virologic response (IVR, defined as a decrease in serum HBV below 4 log10copies/mL after 6 month of treatment) and adefovir resistance in lamivudine resistant HBV-infected patients.
This study population comprised 76 patients with lamivudine-resistance who had received adefovir for more than 12 months between March 2004 and December 2006. The adefovir-resistant mutant was assayed at 6 months and 12 months during adefovir administration. Restriction- fragment mass polymorphism analysis was used for detecting YMDD and adefovir mutants.
After adefovir administration, an IVR was observed in 31% of the patients with lamivudine resistance. Factors associated with an IVR were HBeAg negativity (P=0.04) and the presence of liver cirrhosis (P=0.04). Age, sex, pretreatment levels of alanine aminotransferase and aspartate aminotransferase, pretreatment HBV DNA levels, presence of precore mutation, and type of YMDD mutants were not related to an IVR during adefovir treatment. The prevalence of adefovir resistance was 5% and 13% at 6 months and 12 months after therapy, respectively. Mixed infection of the precore mutant was a risk factors for the emergence of adefovir resistance (P=0.01).
Lamivudine-resistant HBV patients exhibiting HBeAg negativity and liver cirrhosis were more likely to achieve an IVR after adefovir therapy. Adefovir resistance was associated with mixed infection of the precore mutant. (Korean J Hepatol 2008;14:58-66)
KeyWords: Adefovir, Hepatitis B, Lamivudine, Drug resistance
PDF Links  PDF Links
Full text via DOI  Full text via DOI
Download Citation  Download Citation
CrossRef TDM  CrossRef TDM
Related articles
Virologic response is not durable after adefovir discontinuation in lamivudine-resistant chronic hepatitis B patients  2011 December;17(4)
Impact of prior lamivudine use on the antiviral efficacy and development of resistance to entecavir in chronic hepatitis B patients  2015 June;21(2)
No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients  2014 June;20(2)
Efficacy and predictors of the virologic response to entecavir therapy in nucleoside naive patients with chronic hepatitis B  2010 March;16(1)
The Korean Journal Of Clinical outcomes and development of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients  2009 September;15(3)
Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051   FAX: +82-2-703-0071    E-mail: kasl@kams.or.kr
About |  Browse Articles |  Current Issue |  For Authors and Reviewers
Copyright © The Korean Association for the Study of the Liver. All rights reserved.